FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On November 13, 2017, Fibrocell Science, Inc. issued a press release announcing financial results for the three and nine months ended September 30, 2017 and recent operational highlights. A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated November 13, 2017 |
EXHIBITINDEX
|
Exhibit No. |
Description |
|
Press Release dated November 13, 2017
|
Fibrocell Science, Inc. ExhibitEX-99.1 2 exhibit991pressrelease1113.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST -EXTON,…To view the full exhibit click here
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
